Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Alex F. Herrera(City of Hope), Matthew J. Matasar(Rutgers, The State University of New Jersey), Jonathon B. Cohen(Emory University), Geoffrey Shouse(City Of Hope National Medical Center), Steven T. Rosen(Unknown), James Godfrey(City of Hope), Lacolle Peters(City Of Hope National Medical Center), Sandrine Puverel(Scientific Centre of Monaco), Stephen J. Forman(City Of Hope National Medical Center), Ranjana H. Advani(Stanford Medicine), Matthew Mei(City of Hope), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Lihua E. Budde(City Of Hope National Medical Center), Ann S. LaCasce(Otsuka (Japan)), Shari Daniels(City of Hope), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lu Chen(City of Hope), Liana Nikolaenko(City Of Hope National Medical Center), Swetha Kambhampati(City Of Hope National Medical Center), Leslie Popplewell(City Of Hope National Medical Center)
Cited by 18
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k